Enhancing chemotherapeutic efficacy: Niosome‐encapsulated Dox‐Cis with <scp>MUC</scp>‐1 aptamer
The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.
Authors
- Didem Ag Seleci (ORCID: https://orcid.org/0000-0002-7582-1431)
- Suna Tımur (ORCID: https://orcid.org/0000-0002-1981-7577)
- Zinar Pınar Gümüş (ORCID: https://orcid.org/0000-0002-3192-0614)
- Frank Stahl (ORCID: https://orcid.org/0000-0001-7416-0806)
- Fırat Barış Barlas (ORCID: https://orcid.org/0000-0001-6401-686X)
- Pınar Si̇yah (ORCID: https://orcid.org/0000-0003-1192-9416)
- Thomas Scheper (ORCID: https://orcid.org/0000-0003-1535-4584)
- Bilge Ölçeroğlu
- Meriam Dabbek
- Georg Garnweitne
Institutions
- Leibniz University Hannover (DE)
- Bahçeşehir University (TR)
- Ege University (TR)
- Istanbul University-Cerrahpaşa (TR)
- Technische Universität Braunschweig (DE)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1002/cam4.70079
- Citations
- 6
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.04
Funders
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu